BioCorRx Inc. · OTC:BICX
BioCorRx — Investor Presentation (November 2018)
37 slides from BioCorRx's investor presentation, Nov 9, 2018
Slide 1: BioCorRx
J ¥ | , . BioCorRx
Slide 2: Safe Harbor Statement
es BioCorRxef Safe Harbor Statement The information in this investor presentation may include forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," “plan,” "will," and similar expressions, These forward-looking
Slide 3: Investment Highlights
ee PC oRRX 3 Investment Highlights Y The addiction treatment market represents a multi-billion dollar industry which is undergoing a radical transformation to new treatment modalities involving medications. Y BioCorRx has a two business models for treating addiction aligned with this change: * Seeki
Slide 4: Company Overview
Lee isCoikke® Company Overview Substance abuse and addiction treatment company offering a two-pronged approach to the treatment of substance abuse addiction BioCorRxeg Holding Company BioCorRxef [Pharmaceuticals BioCorRxef [Recovery Program Commercialization of naltrexone implant: BICK102, focused o
Slide 5: The Addiction Epidemic
The Addiction Epidemic Devastating Costs, Imperfect Solutio
Slide 6: The Addiction Epidemic
es BioCorRxef The Addiction Epidemic " Medication-assisted treatment (MAT) ~ the use of medication combined with counseling and behavioral therapies is ‘one of the major pillars of the federal response to the opioid epidemic in this country. This type of treatment is an important tool that has the p
Slide 7: The Opioid Epidemic in the U.S.
ees BioCorRxeg & The Opioid Epidemic in the U.S. In 2015... B 12.5 million People misused prescription opioids! 222:imilion £433001 Bg 2milion ‘postr tat ovegeerg on co ‘Spd ua rae & 15,281 828,000 $9,580 ‘ont arated tes page ited OE Sonor 135,000 12,989 People ved nn | eat abt Tote tt tne ‘oven on
Slide 8: Addiction Treatment Market
es BioCorRxeg Addiction Treatment Market’ Addiction treatment spending has grown faster than the total GDP inflation rate, the medical care inflation rate, and population growth. From 2008- 2014, growth in addiction treatment spending also exceeded growth in total health spending. Spending In 2015 a
Slide 9: Medication Assisted Treatment
el HOTT Cae Medication Assisted Treatment Strong shift towards combining medication and counseling “By its very definition, medication-assisted treatment has to include more than medication alone. It has to include counseling services and the other support services that are an important part of effe
Slide 10: The Big Three
a BioCorRxef The Big Three The Most Common MAT Medications Include: 1) Naltrexone + FOA approved in 1384 —long track record of safety + Non-narcoticand non-addltive + NOT opioid derived (antagonist) + Significantly blocks cravings for drugs and alcohol + Nowithdrawals when ceasing use 2) Methadone +
Slide 11: Naltrexone Science
BioCorRx Naltrexone Science Naltrexone is a unique medication which binds with receptors and prevents the release of Dopamine — reducing cravings for alcohol and drugs Naltrexone was approved by the FDA in 1984, in tablet form, for opioid addiction and approved subsequently in 1994 for alcohol use d
Slide 12: Unlocking Value, Expanding Treatment Systems
BioCorRx Unlocking Value, Expanding Treatment Sy
Slide 13: BioCorRx Pharmaceuticals: Naltrexone Implant BICX102
al BioCoukx BioCorRx® Pharmaceuticals Naltrexone Implant BICX102 — for the treatment of opioid and alcohol use disorders Acquired North American rights to new implant formulations and Prodetoxone study data in 2016* + Extended release implant providing a therapeutic effect and maintain plasma levels
Slide 14: BioCorRx Pharmaceuticals: Naltrexone Injectable BICX101
BioCorRxef BioCorRx® Pharmaceuticals Naltrexone Injectable BICX101 — for the treatment of opioid and alcohol use disorders * Acquired Therakine patents and technology for development of a new injectable version of naltrexone using underlying patented and patent pending technology * Utilizing Theraki
Slide 15: Competitive Landscape — Addiction Implants
es BisCoukx Competitive Landscape — Addiction Implants Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn Pharmaceuticals Current buprenorphine implant product: + FDA approved buprenorphine implant in May 2016- six- month subdermal implant developed by Titan Pharmaceuticals J ipeerthe snot + Braeburn
Slide 16: Competitive Landscape — Naltrexone
Dh BioCorRxef Competitive Landscape — Naltrexone Vivitrol® (Alkermes PLC, NASDAQ:ALKS) Long lasting injectable naltrexone product: + FDA approved sustained release naltrexone Injection - lasts up to 30 days + Strong demand - over ~$200 million in sales in 2016 + Parent Company Alkermes ~$9 billion m
Slide 17: Key Advantages of Naltrexone Implant BICX102
——;;;;;_;;_;_;;_;_————— Key Advantages of Naltrexone Implant BICX102 Advantages over buprenorphine implant: Y Addresses both alcoholism and opioid addiction Y Biodegrades eliminating the need to remove and replace Y Non-addictive active pharmaceutical ingredient v Known to be effective against other
Slide 18: R&D & FDA Objectives & Milestones
BioCorRxef R&D & FDA Objectives & Milestones + Retained Dr. David Gastfriend — previously served as VP of Scientific Communications for Alkermes; heavily involved with Vivitrol® * Retained Dr. Bal S. Brar as a lead drug development study design consultant ~ over 25 years of experience for drug and d
Slide 19: R&D & FDA Objectives & Milestones (cont.)
Se yt R&D & FDA Objectives & Milestones (cont.) + Retained Innovative Science Solutions, LLC, a leading scientific consulting firm, to help guide the Company's regulatory strategy for FDA submission * Held FDA Pre-IND meeting on January 24, 2018 + 505(B)(2) pathway deemed acceptable by FDA + Asa res
Slide 20: BioCorRx: Weight Loss Program
BioCorRx®: Weight Loss Program
Slide 21: BioCorRx Medication-assisted Weight Loss Program
LL i 3 BioCorRx® Medication-assisted Weight Loss Program BICX103 Proprietary Naltrexone Implant’ - cleared for use under state and federal compounding fules * Implant inserted in fatty tissue of abdomen * Simple outpatient procedure by licensed medical professional + Procedure only takes 20-30 minut
Slide 22: Weight Loss Program Pilot Results
eT | BioCorRxeg BioCorRx® Medication-assisted Weight Loss Program Pilot Weight Loss Pilot Results? * 6 month study initiated in November 2017 + 18 participants with a BMI of 33 or greater and body fat percentage of 35% or higher were enrolled + Candidates were asked to commit to a 6-month program th
Slide 23: Weight Loss Program Pilot Results
es BioCorRxef BioCorRx® Medication-assisted Weight Loss Program Pilot Weight Loss Pilot Results? won Weight Loss Aiea Weiter weds mvaigeattweds MWsioneemets 8) 2meats meen eS ent Sponsors: Crs ne, Henin S. Goncale, MD andl ames LaValle, RP, CCN lead investigaton: Benji 5 Gonale, MD and James taal, R
Slide 24: Weight Loss Program Pilot Results
es BioCorRxeg BioCorRx® Medication-assisted Weight Loss Program Pilot Weight Loss Pilot Results? + Randomized, 3 month ongoing study initiated in September 2018 * 6 participants aged 27 to<SS * Candidates were asked to commit to a 3-month program that included semi-monthly plasma levels. The primary
Slide 25: Weight Loss Program Pilot Results
es BioCouks 3 BioCorRx® Medication-assisted Weight Loss Program Pilot Weight Loss Pilot Results? Projected Body Mass tndex (2M) Participant teil wna ‘Month 1 Month 2 Month 3 7063 ane aa 335 27 2508 aaa ane 329 32a 4521 354 as 339 332 4189, 466 458 452 444 sto. 339 331 324 316 on 329 2 313 304 Projec
Slide 26: Weight Loss Program Pilot Results
LL i 32 BioCorRx® Medication-assisted Weight Loss Program Pilot Weight Loss Pilot Results? nett Projected Weight Loss ‘Sponsors: Core ne, sep OeSanto, MO lead investigator: ab Bra, PHD OTCOB:BICK 26
Slide 27: The BioCorRx Recovery Program
BioCo Rx 4 Non-Addictive Medication-Assisted Ti el The BioCorRx® lecoveryProgram
Slide 28: The BioCorRx Recovery Program — Non-Addictive MAT
eT | BioCorRxeg The BioCorRx® Recovery Program — Non-Addictive Medication-Assisted Treatment (MAT) Proprietary Naltrexone implant! - cleared for use under state and federal compounding rules + Implant inserted in fatty tissue of abdomen, + Simple outpatient procedure by licensed medical professional
Slide 29: BioCorRx Recovery Program Mobile Application
eT BioCorRxeg The BioCorRx® Recovery Program — Non-Addictive Medication-Assisted Treatment (MAT) BioCorRx Recovery Program Mobile Application + Now available on the Apple App Store & Google Play + “Realtime” virtual interaction with Peer Recovery Coach + Geo Location Tracker/optional * Mood Tracker
Slide 30: A Fully Integrated 52-week Program
DE BioCorRxef BioCorRx® Recovery Program: A Fully Integrated 52-week Program 52-Weeks Outpatient Program iageseiey © Saree + Second mare 4-6 mentite rat apson * Feaeion the fire
Slide 31: pusines
pusines i orRx! most ofile we = fe Focused
Slide 32: Management
ee Management BioCorRxeg Brady Granier, BSN: CEO/President, Director ‘+ S:years with BloCorfx Ine. repositioned company as leader in the industry with the acquisition of TheraKine technology and RED Initiative, assembled a team of addiction experts worldwide, extensive experience with treatment of p
Slide 33: Management
Management Brady Granier CEO/President brady@BioCorRx.com Lourdes Felix CFO/coo Hf@BioCorRx.com OTCOB:BICK BioCorRxef 2390 E. Orangewood Ave. Suite 575 Anaheim, CA (714) 462-4880 www,BioCorRx.com www.beataddiction.com 33
Slide 34: Appendix: Patent Portfolio
————— Appendix: Patent Portfolio 7 ic omen material, method for Prriosds ‘manufacturing thereof and 31/30/2011 e/14/2016 ee 11/30/2031 euticals ryethods for delivery ofa drug- i delivery composition Hydrophobic drug-delvery BiocorRx material, method for Pharmaceuticals manufacturing thereat and auyp
Slide 35: Appendix: Patent Portfolio
a 0 Appendix: Patent Portfolio BRecnresy Programe BioCorRx micronized Delivery Material Pharmaceuticals and Method for Manufacturing Use of Meso-and Nanoporous ‘Material for Surfactant ‘Trapping in Nanoparticle Suspensions Use of Meso- and Nanoporous ioCorRe Pharmaceuticals BlocorRx Material for Sur
Slide 36: Appendix: Patent Portfolio Continued
Ss cc Appendix: Patent Portfolio Continued — Hydrophobic drug-delivery BioCorRx material, method for Pharmaceuticals manufacturing thereof and 11/29/2012 3/29/2017 «EP Patent 2788324 11/29/2032 methods for delivery ofa drug- oe sy es rnemcecaehsrremtingad” MEIC ang uesen gy Preparation and Applicati
Slide 37: Appendix: Patent Portfolio Continued
Appendix: Patent Portfolio Continued — ‘Subcutaneous blodegradeable siocorkxine, naltrexone implant and behavioral program for sojos/2o18 pending 16, 150/154 weight loss OTCOB:BICK 7